Аннотация:
Background: As in many other developed nations, the problem of obesity and type 2 diabetes is acute in Russia. In Russia, the only combination of sibutramine and metformine (Reduxin®Met) is authorized to reduce body mass and prevention development of type 2 diabetes mellitus or its complication. The article presents the results of the observational program “AVRORA”. Aim: Evaluation of the effectiveness and safety of Reduxin®Met (sibutramine + microcrystalline cellulose + Metformin) in patients with type 2 diabetes and alimentary obesity in routine clinical practice. Materials & methods: The observational program “AVRORA” was conducted from September 2016 to October 2017 under the auspices of the Endocrinological Scientific Center and the Russian Association of Endocrinologists. The “AVRORA” program was a multicenter, non-interventional study of patients to whom the attending physicians prescribed Reduxin®Met, a set (tablets + capsules), in accordance with the instruction for medical us
Дедов И. И. Иван Иванович 1941-
Романцова Т. И. Татьяна Ивановна 1959-
Шестакова М. В. Марина Владимировна 1962-
Dedov I. I. Ivan Ivanovich 1941-
Romantsova T. I. Tat`yana Ivanovna 1959-
Shestakova M. V. Marina Vladimirovna 1962-
Rational approach to patients treatment with type 2 diabetes and obesity: Results of the All-Russian observational program «AURORA» [РАЦИОНАЛЬНЫЙ ПОДХОД К ТЕРАПИИ ПАЦИЕНТОВ С СД2 И ОЖИРЕНИЕМ: ИТОГИ ВСЕРОССИЙСКОЙ НАБЛЮДАТЕЛЬНОЙ ПРОГРАММЫ «АВРОРА»]
Rational approach to patients treatment with type 2 diabetes and obesity: Results of the All-Russian observational program «AURORA» [РАЦИОНАЛЬНЫЙ...
Текст визуальный непосредственный
Ожирение и метаболизм
Федеральное государственное бюджетное учреждение Национальный медицинский исследовательский центр эндокринологии Министерства здравоохранения Российск
Т. 15, Вып. 4 С. 48-58
2018
Статья
All-Russian observational program “AVRORA” Obesity Reduxine Reduxine®Met Sibutramine Type 2 diabetes
Background: As in many other developed nations, the problem of obesity and type 2 diabetes is acute in Russia. In Russia, the only combination of sibutramine and metformine (Reduxin®Met) is authorized to reduce body mass and prevention development of type 2 diabetes mellitus or its complication. The article presents the results of the observational program “AVRORA”. Aim: Evaluation of the effectiveness and safety of Reduxin®Met (sibutramine + microcrystalline cellulose + Metformin) in patients with type 2 diabetes and alimentary obesity in routine clinical practice. Materials & methods: The observational program “AVRORA” was conducted from September 2016 to October 2017 under the auspices of the Endocrinological Scientific Center and the Russian Association of Endocrinologists. The “AVRORA” program was a multicenter, non-interventional study of patients to whom the attending physicians prescribed Reduxin®Met, a set (tablets + capsules), in accordance with the instruction for medical us